horizontherapeutics
New York (AFP) - US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion. The California-based company said it will pay cash to the tune of $116.50 a share in Horizon Therapeutics, a 20 percent premium over Horizon's closing price Friday on Wall Street, in what would be the biggest deal of the year in the health sector. The bid will be financed through a bank lending facility. Founded in 2005, Horizon Therapeutics develops and markets drugs for rare, auto-immune and...
AFP
Discusses the partnership and the potential income it might generate with some highlights from the recent Q3 result Technology-based biopharma company Xeris (NASDAQ:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (NASDAQ:HZNP). Xeris opened 12.6% higher at $1.43 on the news before traders banked profits, with the stock drifting lower and closing with a 3.9% gain at $1.32 on Wednesday afternoon. Q3 2022 hedge fund letters, conferences and more Find A Qualified Financial Ad...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら